MentionFox
Home › Who owns › Zevra Therapeutics, Inc.
Owners, funding and legal record

Who owns Zevra Therapeutics, Inc.? Owners, funding and legal record

Before you sign with, sell to or invest in Zevra Therapeutics, Inc.

MentionFox check on Zevra Therapeutics, Inc.: no red flags found in 9 sources (checked 15 November 2026). mentionfox.com/c/who-owns/zevra-therapeutics

Check Zevra Therapeutics, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Zevra Therapeutics, Inc.?

Zevra Therapeutics, Inc. is a publicly traded company (Nasdaq: ZVRA). The most recent 5%+ ownership report names Fidelity (FMR) holding 9.4% (Schedule 13G/A, filed 2026-11-05).

As of November 15, 2026, Zevra Therapeutics, Inc. is a publicly traded company (Nasdaq: ZVRA); its largest reported holder is Fidelity (FMR), with 9.4% on Schedule 13G/A of November 5, 2026, then Woodline Partners LP (8.1%). The largest insider holding is Neil F. McFarlane, the chief executive and president, with 417,225 shares (0.70% of shares outstanding), per Form 4 of October 13, 2026 (Schedule 13G/A, November 5, 2026).

Woodline Partners LP also filed stake reports on 19 other companies ↓

Is this your company?

About to sign with, pay or invest in Zevra Therapeutics, Inc.? See the free Snapshot first.

Watch Zevra Therapeutics, Inc.

Free to see. No signup.

Is Zevra Therapeutics, Inc. a real, registered company?

Before you sign or pay

Who are Zevra Therapeutics, Inc.'s owners and officers?

Zevra Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).

ReportHolderShare
Schedule 13G/A, 2026-11-05Fmr LLC9.4%
Schedule 13G/A, 2026-08-14Woodline Partners LP8.1%
Schedule 13G/A, 2026-08-06Fmr LLC8.3%
Schedule 13G, 2026-07-31Vanguard Capital Management5.11%
Schedule 13G, 2026-05-06Fmr LLC5.5%
Schedule 13G/A, 2026-03-27The Vanguard Group0%
Schedule 13G/A, 2025-11-14Woodline Partners LP6.2%
Schedule 13G/A, 2025-11-13Adage Capital Management, L.P.3.96%

Questions about who owns Zevra Therapeutics, Inc.

Who owns Zevra Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Zevra Therapeutics, Inc.: Fmr LLC (9.4%, Schedule 13G/A, filed 2026-11-05), Woodline Partners LP (8.1%, Schedule 13G/A, filed 2026-08-14) and Vanguard Capital Management (5.11%, Schedule 13G, filed 2026-07-31).

Who are the largest shareholders of Zevra Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Zevra Therapeutics, Inc. on this page are Fmr LLC (9.4%), Woodline Partners LP (8.1%) and Vanguard Capital Management (5.11%).

When did Fmr LLC buy into Zevra Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-06, reporting 5.5%; its latest, Schedule 13G/A filed 2026-11-05, reports 9.4%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Want the whole picture on Zevra Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Zevra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Zevra Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.
FiledPersonRoleChangeEffective
Form 8-K, 2026-03-09Justin RenzChief Financial Officerappointed2026-03-09

Which insiders own Zevra Therapeutics, Inc. shares?

Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.

Shares outstanding: 59,504,621 as of 2026-10-30, from the company's latest SEC cover page.

How much has Zevra Therapeutics, Inc. raised?

No fundraising or offering filing from Zevra Therapeutics, Inc. is on file with us.

Keep reading

More on Zevra Therapeutics, Inc. and the records around it.

Zevra Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Related pages

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

Not for employment, credit, insurance or tenancy decisions.

Cite this page

Permanent URL: https://mentionfox.com/who-owns/zevra-therapeutics
Last updated 2026-11-15
Who owns Zevra Therapeutics? Publicly traded (Nasdaq: ZVRA). MentionFox, 2026-11-15. https://mentionfox.com/who-owns/zevra-therapeutics